TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06488290: ALKAZAR: Phase 3 Randomized Trial of Neladalkib (NVL-655) vs Alectinib in Treatment-Naive ALK-Positive Advanced NSCLC

Sponsor: Nuvalent, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06488290 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06488290 Rescue Dossier →